We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05866536
Recruitment Status : Recruiting
First Posted : May 19, 2023
Last Update Posted : May 30, 2023
Information provided by (Responsible Party):
Denise Louise Faustman, MD, Massachusetts General Hospital

Brief Summary:
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Type 1 Diabetes Diabetes type1 Autoimmune Diabetes Biological: Bacillus Calmette-Guérin Biological: Saline Injection Phase 2

Detailed Description:

Published Phase I data on repeat BCG vaccinations in long term adult type 1 diabetics showed specific death of some of the disease causing bad white blood cells and also showed a short and small pancreas effect of restored insulin secretion. The BCG vaccine also had beneficial metabolic effects that resets the utilization of sugars and significantly improves blood sugars by stably lowering HbA1c values for up to 8 years in subjects in the treatment group and not in the placebo group. In this new onset Phase II Pediatric study, the investigators will attempt to test if even more significant effects can be seen in a new onset pediatric population.

Eligible volunteers will either be vaccinated with BCG twice, one month apart or receive a placebo treatment. Both groups will be followed for five years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
Actual Study Start Date : May 4, 2023
Estimated Primary Completion Date : May 2028
Estimated Study Completion Date : May 2028

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bacillus Calmette-Guérin
2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Biological: Bacillus Calmette-Guérin
2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Other Name: BCG

Placebo Comparator: Saline Injection
2 placebo injections spaced 4 weeks apart at the beginning of the trial
Biological: Saline Injection
2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial

Primary Outcome Measures :
  1. Change in HbA1c values [ Time Frame: 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 years after initial BCG/placebo injection ]
    A change in hemoglobin A1c (HbA1c) values for new onset pediatric type 1 diabetics compared to self.

Secondary Outcome Measures :
  1. Change in C-peptide [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ]
    A change of fasting or stimulated C-peptide (as an analog for endogenous insulin) in the blood compared to self.

  2. Change in insulin usage [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ]
    A change in insulin usage with IDAA1c calculation (adjusting for weight and HbA1c) compared to self.

Other Outcome Measures:
  1. Exploratory: Change in hypoglycemia [ Time Frame: 1, 2, 3, 4, and 5 years after initial BCG/placebo injection ]
    A change in hypoglycemic episodes or the magnitude of blood sugar fluctuations compared to self.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, Age 8 - <18 years at the time of study entry and <18 at the time of randomization.
  • Type 1 diabetic subjects diagnosed more than 3 months ago and less than 12 months ago
  • Previously diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by laboratory analysis as per local guidelines) prior to study enrollment by WHO/ADA diagnostic criteria for glucose levels (FPG = 7.0 mmol/L [126 mg/dL]) or plasma glucose levels 2-hours after 75-gm oral glucose load of = 11.1 mmol/L (200 mg/dL) or a casual plasma glucose >200 mg/dL with symptoms.
  • Presence of one or more of the following: antibodies to glutamic acid decarboxylase (GAD), islet cell autoantibody (ICA), protein tyrosine phosphatase-like protein antibodies (IA-2), Insulin autoantibodies (IAA), zinc transporter 8 antibodies (ZnT8).
  • Ongoing daily treatment with insulin prior to the screening visit.
  • HIV antibody negative, M. tuberculosis (TB) negative (QuantiFERON-TB test negative), human chorionic gonadotropin (hCG) negative
  • Normal CBC and chemistries and only Grade 1 creatinine elevations
  • Informed consent and child assent, as age-appropriate, obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. Legally Acceptable Representative (LAR) of the Subject must sign and date the Informed Consent Form (according to local requirements). The child must sign and date the Child Assent Form or provide oral assent, if required according to local requirements.

Exclusion Criteria:

  • History of tuberculosis, positive interferon-gamma release assay (IGRA, also known as the QuantiFERON-TB test), including a test with a high reactivity to mycobacteria of non-tuberculosis variety
  • History of prior BCG vaccination, positive T-spot tuberculosis test or a T-spot test showing significant Mycobacteria exposure
  • Not born in the US or born in a country with mandatory BCG vaccinations.
  • Previous participation in the treatment group in biologic or drug intervention trials for Type 1 diabetes such as anti-CD3
  • Simultaneous participation in any other clinical trial while enrolled in this clinical trial or participation in another clinical trial within 28 days before the screening visit Note: Clinical trials do not include non-interventional studies.
  • Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs
  • Current treatment with antibiotics or need for chronic antibiotics
  • Current treatment with glucocorticoids (other than intermittent nasal or eye steroids, asthma inhaler, or topical steroids), or disease or condition likely to require high dose steroid or immunosuppressive therapy
  • Anticipated initiation or change in concomitant medication in excess of 14 days known to affect glucose metabolism (e.g. thyroid hormones, corticosteroids)
  • Currently on or planning to be taking any oral type 2 diabetes drug or other oral blood sugar lowering medication or dramatically changing their standard of care .
  • Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria in a period of 90 days before screening
  • History of keloid formation
  • History of lupus
  • Monogenetic diabetes
  • Diabetes secondary to cystic fibrosis
  • History of type 2 diabetes or severe obesity
  • Known hypoglycemic unawareness or recurrent severe hypoglycemic episodes as judged by the Investigator
  • More than one episode of diabetic ketoacidosis requiring hospitalization within the last 90 days prior to the screening
  • History of recurrent ketoacidosis with hospitalizations due to non-compliance
  • History of active proliferative diabetic retinopathy
  • History or evidence of chronic kidney disease (serum creatinine > 1.5mg/dL), significant protein in the urine, or other significant and/or active diabetes related complication
  • History of significant neuropathy, myocardial infarcts, active psychiatric disease that might preclude travel and long-term participation, dementia, foot ulcers, severe diabetes non-compliance, amputations, or kidney disease
  • Diagnosis of malignant neoplasms within the last five years prior to the screening visit
  • History of medical condition(s) that may impact red blood cell turnover such as polycythemia, chronic anemia, vitamin E infusion, transfusion, sickle cell or thalassemia, vitamin C injections, lead poisoning, uremia, or asplenia.
  • Other chronic conditions, diseases and/or treatments associated with increased risk of serious side effects or morbidities. Such conditions that increase the risk of infections with immunosuppressive therapies for other autoimmune diseases, patients with a previous history of severe burns, or treatment with immunosuppressive medications of any type (e.g., imuran, methotrexate, cyclosporine, etanercept, infliximab) for any reason
  • History of chronic infectious disease, such as HIV or untreated or active hepatitis
  • Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example, HIV+ or taking immunosuppressive medications for any reason)
  • Known or suspected hypersensitivity to trial products or related products
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
  • Any condition, which, in the opinion of the Investigator, might jeopardize the Subject's safety or compliance with the protocol
  • Current BMI of <5th percentile or >95th percentile
  • Blood pressure >90th percentile for their age and sex
  • Temperature >98.6 F
  • Heart rate outside of 50-120 bpm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05866536

Layout table for location contacts
Contact: Denise L Faustman, MD, PhD 617-726-4084 diabetestrial@partners.org

Layout table for location information
United States, Massachusetts
Immunobiology Labs CNY 149 Recruiting
Charlestown, Massachusetts, United States, 02129
Contact: Denise L Faustman, MD, PhD    617-726-4084    diabetestrial@partners.org   
Principal Investigator: Denise L. Faustman, MD, PhD         
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Denise L Faustman, MD, PhD Massachusetts General Hospital
Additional Information:
Layout table for additonal information
Responsible Party: Denise Louise Faustman, MD, Director of the Immunobiology Laboratory, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT05866536    
Other Study ID Numbers: 2019P002835-RO
First Posted: May 19, 2023    Key Record Dates
Last Update Posted: May 30, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Denise Louise Faustman, MD, Massachusetts General Hospital:
Diabetes Mellitus
Type One Diabetes Mellitus
Type I Autoimmune Diabetes Insulin Dependent Diabetes Mellitus 1 IDDM
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs